Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 9 |
| List of Tables | 9 | 1 |
| List of Figures | 10 | 1 |
| Introduction | 11 | 1 |
| Global Markets Direct Report Coverage | 11 | 1 |
| Hemophilia A Overview | 12 | 1 |
| Therapeutics Development | 13 | 2 |
| Pipeline Products for Hemophilia A Overview | 13 | 1 |
| Pipeline Products for Hemophilia A Comparative Analysis | 14 | 1 |
| Hemophilia A Therapeutics under Development by Companies | 15 | 2 |
| Hemophilia A Therapeutics under Investigation by Universities/Institutes | 17 | 1 |
| Hemophilia A Pipeline Products Glance | 18 | 4 |
| Late Stage Products | 18 | 1 |
| Clinical Stage Products | 19 | 1 |
| Early Stage Products | 20 | 1 |
| Unknown Stage Products | 21 | 1 |
| Hemophilia A Products under Development by Companies | 22 | 3 |
| Hemophilia A Products under Investigation by Universities/Institutes | 25 | 1 |
| Hemophilia A Companies Involved in Therapeutics Development | 26 | 30 |
| Alnylam Pharmaceuticals Inc | 26 | 1 |
| Amarna Therapeutics BV | 27 | 1 |
| Apitope International NV | 28 | 1 |
| Bayer AG | 29 | 1 |
| Biogen Inc | 30 | 1 |
| BioMarin Pharmaceutical Inc | 31 | 1 |
| Catalyst Biosciences Inc | 32 | 1 |
| Chugai Pharmaceutical Co Ltd | 33 | 1 |
| CSL Ltd | 34 | 1 |
| DBV Technologies SA | 35 | 1 |
| Dimension Therapeutics Inc | 36 | 1 |
| Emergent BioSolutions Inc | 37 | 1 |
| EpiVax Inc | 38 | 1 |
| Expression Therapeutics LLC | 39 | 1 |
| Green Cross Corp | 40 | 1 |
| Idogen AB | 41 | 1 |
| Lentigen Technology Inc | 42 | 1 |
| mAbxience SA | 43 | 1 |
| Novo Nordisk A/S | 44 | 1 |
| Octapharma AG | 45 | 1 |
| OPKO Biologics Ltd | 46 | 1 |
| Pfizer Inc | 47 | 1 |
| Pharming Group NV | 48 | 1 |
| rEVO Biologics Inc | 49 | 1 |
| Sangamo BioSciences Inc | 50 | 1 |
| Shire Plc | 51 | 1 |
| SK Chemicals Co Ltd | 52 | 1 |
| Spark Therapeutics Inc | 53 | 1 |
| UniQure NV | 54 | 1 |
| XL-protein GmbH | 55 | 1 |
| Hemophilia A Therapeutics Assessment | 56 | 9 |
| Assessment by Monotherapy Products | 56 | 1 |
| Assessment by Target | 57 | 2 |
| Assessment by Mechanism of Action | 59 | 2 |
| Assessment by Route of Administration | 61 | 2 |
| Assessment by Molecule Type | 63 | 2 |
| Drug Profiles | 65 | 76 |
| antihemophilic factor Drug Profile | 65 | 4 |
| antihemophilic factor (human) Drug Profile | 69 | 4 |
| antihemophilic factor (recombinant) Drug Profile | 73 | 1 |
| antihemophilic factor (recombinant) Drug Profile | 74 | 1 |
| antihemophilic factor (recombinant) Drug Profile | 75 | 1 |
| antihemophilic factor (recombinant) Drug Profile | 76 | 1 |
| antihemophilic factor (recombinant) Drug Profile | 77 | 1 |
| antihemophilic factor (recombinant) Drug Profile | 78 | 1 |
| antihemophilic factor (recombinant) biosimilar Drug Profile | 79 | 1 |
| antihemophilic factor (recombinant) biosimilar Drug Profile | 80 | 1 |
| antihemophilic factor (recombinant), pegylated Drug Profile | 81 | 2 |
| antihemophilic factor (recombinant), single chain Drug Profile | 83 | 3 |
| ATXF-8117 Drug Profile | 86 | 1 |
| BAX-888 Drug Profile | 87 | 1 |
| BAY-1093884 Drug Profile | 88 | 1 |
| BMN-270 Drug Profile | 89 | 2 |
| Cell Therapy to Target Coagulation Factor VIII for Hemophilia A Drug Profile | 91 | 1 |
| coagulation factor VIIa (recombinant) Drug Profile | 92 | 2 |
| coagulation factor VIII (human) Drug Profile | 94 | 1 |
| concizumab Drug Profile | 95 | 1 |
| CSL-689 Drug Profile | 96 | 2 |
| damoctocog alfa pegol Drug Profile | 98 | 2 |
| Deimmunized FVIII Drug Profile | 100 | 1 |
| DTX-201 Drug Profile | 101 | 1 |
| emicizumab Drug Profile | 102 | 3 |
| ET-3 Drug Profile | 105 | 1 |
| fitusiran Drug Profile | 106 | 6 |
| Gene Therapy for Hematological Disorders Drug Profile | 112 | 1 |
| Gene Therapy for Hemophilia A Drug Profile | 113 | 1 |
| Gene Therapy to Activate Factor VIII for Hemophilia A Drug Profile | 114 | 1 |
| IN-3012 Drug Profile | 115 | 1 |
| Kovaltry Drug Profile | 116 | 2 |
| LG-889 Drug Profile | 118 | 1 |
| LR-769 Drug Profile | 119 | 2 |
| marzeptacog alfa Drug Profile | 121 | 2 |
| MG-1113A Drug Profile | 123 | 1 |
| MOD-5014 Drug Profile | 124 | 3 |
| PBB-8-IN Drug Profile | 127 | 1 |
| PF-06741086 Drug Profile | 128 | 1 |
| Recombinant Factor VIII Replacement for Hemophilia A Drug Profile | 129 | 2 |
| Recombinant Factor VIII Replacement for Hemophilia A Drug Profile | 131 | 1 |
| Recombinant Protein for Hemophilia A Drug Profile | 132 | 1 |
| Recombinant Proteins for Hemophilia A Drug Profile | 133 | 1 |
| SB-525 Drug Profile | 134 | 1 |
| SB-FVIII Drug Profile | 135 | 2 |
| SHP-656 Drug Profile | 137 | 2 |
| SPK-8011 Drug Profile | 139 | 1 |
| SVF-VIIa Drug Profile | 140 | 1 |
| Hemophilia A Dormant Projects | 141 | 2 |
| Hemophilia A Discontinued Products | 143 | 1 |
| Hemophilia A Product Development Milestones | 144 | 14 |
| Featured News &Press Releases | 144 | 1 |
| Nov 14, 2016: AFSTYLA (rFVIII-SC) - CHMP recommendation | 144 | 1 |
| Nov 03, 2016: Genentech to present data on Emicizumab at American Society of Hematology 2016 Annual Meeting | 144 | 1 |
| Sep 12, 2016: Idogen reports important breakthrough - positive results from proof-of-concept study in human cells | 145 | 1 |
| Aug 26, 2016: Chugai receives Orphan Drug Designation for Emicizumab - Preventing and Reducing the Frequency of Bleeding Episodes in Congenital FVlll Deficiency Patients with Inhibitors | 145 | 1 |
| Aug 01, 2016: Shire Announces FDA Approval of adynovate with BAXJECT III Reconstitution System | 146 | 1 |
| Jul 27, 2016: CSL Behring Presents Pivotal Efficacy Data for AFSTYLA In Adolescents and Children with Hemophilia A at the World Federation of Hemophilia 2016 World Congress | 146 | 2 |
| Jul 27, 2016: Chugai Emicizumab Showed Continued Benefits in Patients with Hemophilia A | 148 | 1 |
| Jul 26, 2016: ADYNOVATE Phase 3 Efficacy and Safety Data in Children to be Showcased During International Congress of the World Federation of Hemophilia | 149 | 1 |
| Jul 26, 2016: Sangamo BioSciences Announces New Gene Therapy Clinical Development Program for Treatment Of Hemophilia A | 150 | 1 |
| Jul 25, 2016: Alnylam Announces New Positive Interim Phase 1 Study Results for Fitusiran, a Once-Monthly, Subcutaneous, Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia and Rare Bleeding Disorders | 151 | 3 |
| Jul 25, 2016: Alnylam to Report New Clinical Results with Fitusiran at the World Federation of Hemophilia 2016 World Congress | 154 | 1 |
| Jul 19, 2016: Shire reinforces commitment in Hematology with robust data presented at international congress of the World Federation of Hemophilia | 154 | 1 |
| Jul 19, 2016: CSL Behring to Present New Data for AFSTYLA at the World Federation of Hemophilia 2016 World Congress | 155 | 1 |
| Jul 18, 2016: Biogen and Sobi to Showcase Data on FVIIIFc-VWF-XTEN at World Federation of Hemophilia 2016 World Congress | 156 | 1 |
| Jun 20, 2016: AFSTYLA - CSL Behring Novel Recombinant Factor VIII Single Chain Therapy for Hemophilia A - Now Available in the U.S. | 156 | 2 |
| Appendix | 158 | 2 |
| Methodology | 158 | 1 |
| Coverage | 158 | 1 |
| Secondary Research | 158 | 1 |
| Primary Research | 158 | 1 |
| Expert Panel Validation | 158 | 1 |
| Contact Us | 158 | 1 |
| Disclaimer | 159 | 1 |